Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135646 | 1.00 | GPR119 (0.46) | GPR119PRMT5WDR77BRD3MGLL | |
| SCHEMBL15626890 | 0.92 | GPR119 (0.48) | GPR119PRMT5WDR77BRD3MGLL | |
| SCHEMBL4127157 | 0.92 | GPR119 (0.48) | GPR119PRMT5WDR77BRD3MGLL | |
| SCHEMBL4127152 | 0.92 | GPR119 (0.48) | GPR119PRMT5WDR77BRD3MGLL | |
| SCHEMBL31162185 | 0.87 | EPHX2 (0.49) | GPR119PRMT5WDR77BRD3MGLL | |
| SCHEMBL4136707 | 0.85 | PRMT5 (0.52) | GPR119PRMT5WDR77USP30 | |
| SCHEMBL4136705 | 0.85 | PRMT5 (0.52) | GPR119PRMT5WDR77USP30 | |
| SCHEMBL13832706 | 0.83 | GPR119 (0.47) | GPR119PRMT5WDR77BRD3MGLL | |
| SCHEMBL15626897 | 0.83 | GPR119 (0.47) | GPR119PRMT5WDR77BRD3MGLL | |
| SCHEMBL13060199 | 0.83 | DPP4 (0.52) | GPR119BRD3MGLLDPP4HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | PFIZER PRODUCTS INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1931653-A2 | THERAPEUTIC PYRROLIDINES | Pfizer Products Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031828-A2 | THERAPEUTIC PYRROLIDINES | PFIZER PRODUCTS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | OPRL1, HTR5A, OPRD1 | GPR119 1066/4885PRMT5 688/4885WDR77 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.